Kevin Tan Sells 14,783 Shares of Solid Biosciences (NASDAQ:SLDB) Stock

Solid Biosciences Inc. (NASDAQ:SLDB) CFO Kevin Tan sold 14,783 shares of the firm’s stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $6.44, for a total value of $95,202.52. Following the completion of the transaction, the chief financial officer owned 94,201 shares in the company, valued at $606,654.44. This represents a 13.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Kevin Tan also recently made the following trade(s):

• On Monday, February 2nd, Kevin Tan sold 26,837 shares of Solid Biosciences stock. The shares were sold at an average price of $6.44, for a total value of $172,830.28.
• On Tuesday, January 13th, Kevin Tan sold 5,704 shares of Solid Biosciences stock. The shares were sold at an average price of $5.27, for a total value of $30,060.08.

Solid Biosciences Price Performance

SLDB opened at $6.52 on Friday. Solid Biosciences Inc. has a 1 year low of $2.41 and a 1 year high of $7.37. The company has a market capitalization of $507.97 million, a price-to-earnings ratio of -2.62 and a beta of 2.67. The firm’s fifty day moving average price is $5.84 and its two-hundred day moving average price is $5.71.

Institutional Investors Weigh In On Solid Biosciences

Several large investors have recently added to or reduced their stakes in SLDB. Vestal Point Capital LP lifted its holdings in Solid Biosciences by 97.7% during the third quarter. Vestal Point Capital LP now owns 2,975,000 shares of the company’s stock valued at $18,356,000 after purchasing an additional 1,470,000 shares during the last quarter. Nantahala Capital Management LLC raised its position in shares of Solid Biosciences by 505.4% in the second quarter. Nantahala Capital Management LLC now owns 1,703,336 shares of the company’s stock valued at $8,295,000 after purchasing an additional 1,421,968 shares during the period. Geode Capital Management LLC lifted its stake in shares of Solid Biosciences by 184.5% during the 2nd quarter. Geode Capital Management LLC now owns 1,510,153 shares of the company’s stock valued at $7,356,000 after buying an additional 979,294 shares in the last quarter. Bank of America Corp DE lifted its stake in shares of Solid Biosciences by 2,150.4% during the 2nd quarter. Bank of America Corp DE now owns 824,600 shares of the company’s stock valued at $4,016,000 after buying an additional 787,957 shares in the last quarter. Finally, Woodline Partners LP bought a new position in Solid Biosciences in the 1st quarter worth approximately $2,338,000. Hedge funds and other institutional investors own 81.46% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Chardan Capital reaffirmed a “buy” rating and set a $15.00 price target on shares of Solid Biosciences in a research report on Tuesday, November 4th. Needham & Company LLC reaffirmed a “buy” rating and set a $16.00 target price on shares of Solid Biosciences in a research report on Wednesday, January 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Solid Biosciences in a research note on Thursday, January 22nd. Barclays set a $9.00 price target on shares of Solid Biosciences and gave the company an “overweight” rating in a research report on Tuesday, November 4th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Solid Biosciences from $13.00 to $11.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Solid Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.70.

Solid Biosciences News Roundup

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: Company will present at the Guggenheim Emerging Outlook: Biotech Summit (CEO Bo Cumbo presenting Feb 12) — this gives Solid (SLDB) direct exposure to institutional investors and can support a rally if management provides encouraging clinical, regulatory, or financing updates. Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
• Neutral Sentiment: Trading context: SLDB is trading above recent moving averages with volume notably above its average — this suggests heightened interest but does not by itself indicate direction until drivers (presentation vs. insider sales) dominate.
• Negative Sentiment: CEO Alexander (Alex) Cumbo sold 48,913 shares at an average $6.44 (≈$315k); his holding fell ~18.1% — a large CEO sale can be read negatively by investors even if for personal reasons. CEO Sale SEC Filing
• Negative Sentiment: CFO Kevin Tan sold 14,783 shares at $6.44 (~$95k); his position fell ~13.6% — another senior officer reduction that may weigh on sentiment. CFO Sale SEC Filing
• Negative Sentiment: COO David T. Howton sold 18,894 shares at $6.44 (~$122k); ownership declined ~16.2%. COO Sale SEC Filing
• Negative Sentiment: CTO Paul Herzich sold 10,905 shares at $6.44 (~$70k); holding fell ~13.6%. CTO Sale SEC Filing
• Negative Sentiment: Other insiders — director Ilan Ganot (7,205 shares), insider Jessie Hanrahan (12,348 shares), and Gabriel Brooks (12,616 shares) — each sold at $6.44, reducing holdings by double-digit percentages; collectively these sales increase supply pressure and raise investor questions about insider confidence. Director/Insider Sales SEC Filings

Solid Biosciences Company Profile

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.